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Abstract Background: Etamicastat is a novel, potent, and reversible peripheral dopamine-
b-hydroxylase inhibitor that has been administered orally at doses up to
600mg once daily for 10 days to male healthy volunteers and appears to be
well tolerated.
Objective: The aim of this study was to investigate the effect of food on the
pharmacokinetics of etamicastat.
Material and Methods: A single-center, open-label, randomized, two-way
crossover study in 12 healthy male subjects was performed. Subjects were
administered a single dose of etamicastat 200mg following either a standard
high-fat and high-calorie content meal (test) or 10 hours of fasting (reference).
The statistical method for testing the effect of food on the pharmacokinetic
parameters of interest was based upon the 90% confidence interval (CI)
for the test/reference geometric mean ratio (GMR). The parameters of in-
terest were maximum plasma concentration (Cmax), area under the plasma
concentration-time curve (AUC) from time zero to the last measurable con-
centration (AUClast), and AUC from time zero to infinity (AUC¥). Bio-
equivalence was assumed when the 90% CI fell within the recommended
acceptance interval (80, 125).
Results: Etamicastat Cmax,AUClast, andAUC¥were 229ng/mL, 1856ngh/mL,
and 2238 ngh/mL, respectively, following etamicastat in the fasting, and
166 ng/mL, 1737 ngh/mL, and 2119 ngh/mL, respectively, following eta-
micastat in the fed condition. Etamicastat test/reference GMR was 72.27%
(90% CI 64.98, 80.38) for Cmax, 93.59% (90% CI 89.28, 98.11) for AUClast, and
96.47% (90% CI 91.67, 101.53) for AUC¥. Time to Cmax was prolonged by the
presence of food (p< 0.001). TheCmax, AUClast, andAUC¥ values of the inactive
metabolite BIA 5-961 were 275 ng/mL, 1827 ngh/mL, and 2009 ngh/mL,
respectively, in the fasting, and 172ng/mL, 1450ngh/mL, and 1677ngh/mL,
respectively, in the fed condition. BIA 5-961 test/reference GMR was 62.42%
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(90% CI 56.77, 68.63) for Cmax, 79.41% (90% CI 56.77, 68.63) for AUClast,
and 83.47% (90% CI 76.62, 90.93) for AUC¥. A total of six mild to moderate
unspecific adverse events were reported by four subjects. There was no clin-
ically significant abnormality in laboratory assessments.
Conclusion: Etamicastat was well tolerated. The Cmax of etamicastat de-
creased 28% following oral administration of etamicastat in the presence of
food, while AUC remained within the pre-defined acceptance interval. The
delay in absorption and decrease in peak exposure of etamicastat is not
clinically significant, and therefore etamicastat could be administered with-
out regard to meals.
Trial Registration: EudraCT No. 2007-006530-33
Introduction
Activation of the sympathetic nervous system
is an important feature in hypertension and con-
gestive heart failure.[1-6] Inhibition of sympathet-
ic nerve function with adrenoceptor antagonists
appeared to be a promising approach, but a sig-
nificant proportion of patients do not tolerate the
immediate hemodynamic deterioration that ac-
companies b-adrenoceptor antagonist (b-blocker)
treatment, particularly in heart failure patients.[7]
An alternative approach for directly modulating
sympathetic nerve function is to reduce the bio-
synthesis of noradrenaline via inhibition of dopa-
mine-b-hydroxylase (DbH).[8] DbH is a copper II
ascorbate-dependent mono-oxygenase that catal-
yses the conversion of dopamine into noradrenaline
in the catecholamine biosynthetic pathway. The
inhibition of DbH has several putative advantages
over adrenoceptor blockade by conventional adre-
noceptor antagonists (pure b-blockers or mixed
a,b-blockers), such as gradual sympathetic mod-
ulation as opposed to abrupt inhibition, and caus-
ing increased availability of dopamine, which can
improve renal function.[8]
Several DbH inhibitors have been described.
Early first- and second-generation examples, such
as disulfiram[9] and diethyldithiocarbamate[10] or
fusaric acid[11] and aromatic or alkyl thioureas,[12]
were found to be of low potency, exhibited poor
selectivity for DbH, and caused toxic side effects.
A third-generation DbH inhibitor (nepicastat
[RS-25560-197])[8] was found to have much greater
potency and was developed to early clinical trials.
Although devoid of some of the problems associat-
ed with first- and second-generation DbH inhibi-
tors, nepicastat was found to cross the blood-brain
barrier, and was thereby able to cause undesired
and potentially significant CNS-related adverse
events. Therefore, to date, there remains an unmet
clinical need for a potent, safe, and peripherally
selective DbH inhibitor, which could be used for
the treatment of certain cardiovascular disorders
without significant adverse events.
Etamicastat [BIA 5-453; (R)-5-(2-aminoethyl)-
1-(6,8-difluorochroman-3-yl)-1,3-dihydroimid-
azole-2-thione hydrochloride; molecular formula
C14H16ClF2N3OS] was designed by BIAL-Portela
& Co., S. Mamede do Coronado, Portugal, to
act as a reversible inhibitor of peripheral DbH.[13]
In contrast to that found in the peripheral tissues,
etamicastat does not affect dopamine or nor-
adrenaline levels in the brain,[13] which is unique
among DbH inhibitors previously tested for the
treatment of cardiovascular disorders.
Etamicastat was tested in animal models pre-
dictive of efficacy in cardiovascular disorders.[14-16]
Etamicastat reduced systolic and diastolic blood
pressure in spontaneously hypertensive rats
with no changes in normotensive Wistar-Kyotos
rats.[14,15] Etamicastat did not affect heart rate
in spontaneously hypertensive or Wistar-Kyotos
rats. Etamicastat increased survival rates in male
cardiomyopathic hamsters (Bio TO-2 dilated strain)
with advanced congestive heart failure.[16] In
toxicologic studies, the no observed adverse effect
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level was 5mg/kg/day in dogs, 20mg/kg/day in
Cynomolgus monkeys, and 30mg/kg/day in rats
and mice.[17]
The metabolism of etamicastat appears to be
species dependent.[18] In the rat, N-acetylation
appears to be the major metabolic pathway lead-
ing to the formation of BIA 5-961, which is in-
active. All other metabolites were found to occur
in minor amounts and correspond to oxidative
deaminated (BIA 5-965), C-oxidated (BIA 5-998),
and N-oxidated (BIA 5-1016) derivatives of eta-
micastat. In an entry-into-man study[19] in healthy
subjects administered with single oral doses of
etamicastat ranging from 2 to 1200mg, maximum
plasma etamicastat concentrations occurred at
1–3 hours post-dose. Elimination was biphasic,
characterized by a first short early elimination
half-life (t½), followed by a longer elimination
phase of 16–20 hours for etamicastat doses of
‡100mg. Etamicastat underwent N-acetylation
to its inactive metabolite BIA 5-961. The other
putative metabolites did not appear in plasma or
urine. In a subsequent study in healthy sub-
jects,[20] participants received once-daily doses of
placebo or etamicastat 25, 50, 100, 200, 400, or
600mg for 10 days. Etamicastat and BIA 5-961
maximum concentrations were achieved at 1–3
and 2–4 hours, respectively, after dosing. The t½
values ranged from 18.1 to 25.7 hours for etami-
castat and from 6.7 to 22.5 hours for BIA 5-961.
Both etamicastat and BIA 5-961 showed linear
pharmacokinetics. The extent of systemic ex-
posure to etamicastat and BIA 5-961 increased in
an approximately dose-proportional manner, and
steady-state plasma concentrations were attained
up to 9 days of dosing. Approximately 40% of the
etamicastat dose was recovered in urine in the
form of etamicastat and BIA 5-961.
N-Acetyltransferase (NAT) is one of the major
hepatic phase II enzymes involved in drug me-
tabolism. Humans express two functional NAT
isoforms –NAT1 and NAT2.[21] Results from pre-
vious entry-into-man studies[19,20] showed that
the NAT2 phenotype (rapid or slow N-acetylating
ability) is a major source of interindividual vari-
ability in etamicastat pharmacokinetics. ForNAT1,
eight single nucleotide polymorphisms (SNPs)
were analyzed (190 c > t, 445 g > a, 459 g > a, 559 c
> t, 560 g > a, 640 t > g, 1088 t > a, and 1095 c > a)
and the corresponding genotypes were defined
according to the literature.[22,23] Subjects were
classified NAT1 rapid (fast) acetylators if they
carried the NAT1*10 (except NAT1*10/*14) or
NAT1*11 alleles, normal acetylators if they car-
ried the NAT1*4 or NAT1*3 alleles or the
NAT1*10/*14 genotype, and poor (slow) acety-
lators if they carried the NAT1*14 (except
NAT1*10/*14) or NAT1*17 alleles. For NAT2,
four coding SNPswere analyzed (191g > a, 341 t > c,
590 g > a, and 857 g > a) and the corresponding
genotypes were defined according to the liter-
ature.[24,25] Subjects were classified NAT2 rapid
acetylators if they carried the NAT2*4/*4 allele,
or the NAT2*4/*5, NAT2*4/*6 or NAT2*4/*7
genotype, and poor acetylators if they carried the
NAT2*5/*5, NAT2*6/*6 or NAT2*7/*7 alleles,
or the NAT2*5/*6, NAT2*5/*7 or NAT2*6/*7
genotype. The NAT2*4 allele encodes for a fully
active enzyme and is considered the wild-type
(rapid acetylator) allele. Although the NAT1
phenotype showed no relevant effect on etami-
castat pharmacokinetics, the results of previous
entry-into-man studies[19,20] clearly demonstrated
that the NAT2 phenotype had a marked effect on
systemic exposure to etamicastat and BIA 5-961.
The extent of systemic exposure to etamicastat in
NAT2 poor acetylators was approximately twice
that observed in rapid acetylators. Consistent
with this finding, the area under the concen-
tration-time curve (AUC) of the acetylated me-
tabolite BIA 5-961 was markedly higher in NAT2
rapid acetylators compared with poor acetyla-
tors, confirming the involvement of NAT2 in the
biotransformation of etamicastat into BIA 5-961.
Here, the results of an exploratory study aiming
to investigate the effect of food on the pharmaco-
kinetics of a single 200mg oral dose of etamica-
stat in healthy subjects are described.
Subjects and Methods
Study Design
This was a single-center (Biotrial SA, Rennes,
France), open-label, randomized, two-way crossover
study in 12 healthy male subjects. The random-
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ized, balanced, single-dose, two-treatment (fed vs
fasting), two-period, two-sequence crossover de-
sign is a standard for studying the effects of food
on drug bioavailability.[26] The study consisted
of two periods separated by a washout phase of
‡14 days. During each study period, the volun-
teers randomly received a single 200mg oral dose
of etamicastat following either a standard high-
fat and high-calorie content breakfast or 10 hours
of fasting.
During each treatment period, eligible subjects
were admitted to the research facilities on the day
(day 0) prior to receiving the dose of study med-
ication for assessment of vital signs, medical his-
tory, and physical examination, in addition to screen
tests for hematology, plasma biochemistry, and
drug and alcohol abuse. At the beginning of the
first treatment period, the subjects had a review
of the selection criteria and a randomization
number was assigned. The randomization num-
ber defined the treatment sequence to which each
subject was allocated. On the morning of day 1,
etamicastat was administered following a standard
high-fat and high-calorie meal in one treatment
period, or following at least 10 hours of fasting in
another treatment period. Participants remained
confined in the research facilities from admission
(day 0) until at least 72 hours (day 4, discharge)
after dosing. Following the 72 hours post-dose
procedures, participants were discharged, and re-
turned for the next treatment period or a follow-
up visit. Following administration of etamicastat
(four capsules, 50mg) with 240mL of water, in
fasting or fed conditions, a lunch, a snack, and a
dinner were provided at respectively 4, 8, and 12
hours post-dose. Water ad libitum was allowed.
The standard high-fat and high-calorie con-
tent meal was composed of two scrambled eggs,
fried fat bacon (40 g), white bread (60 g), corn
flakes (20 g), whole milk (3% fat, 250mL), and
butter (80% fat, 15 g). A total of approximately
933 kcal was eaten (167 kcal as proteins, 527 kcal
as lipids, and 239 kcal as carbohydrates). The
breakfast was eaten within 30 minutes and drug
administration occurred immediately, thereafter.
The study was conducted according to the
principles of the Declaration of Helsinki and the
Good Clinical Practice guidelines. An Independent
Ethics Committee (CCP Ouest VI, Brest, France)
reviewed and approved the study protocol and
the subject information. Written informed con-
sent was obtained for each subject prior to en-
rollment in the study.
Subjects
Twelve healthymale volunteers aged 18–45 years
with a body mass index (BMI) of 19–28 kg/m2
participated in the study. Healthy condition was
assessed on the basis ofmedical history, physical ex-
amination, electrocardiogram, and clinical labo-
ratory safety tests (hematology, coagulation, plasma
biochemistry, urinalysis, and hepatitis B, hepatitis C,
and HIV serology). Tests for drug and alcohol
abuse were performed at screening and each admis-
sion. No concomitant medication was allowed
during the study, except if required for the treat-
ment of adverse events. During the stays at the
clinical research unit, a standard diet was served,
and alcohol-, caffeine- and grapefruit-containing
food and beverages were prohibited.
Assessment Procedures
A complete medical history and physical ex-
amination were performed at screening and up-
dated at each admission. Clinical adverse events
were monitored throughout the entire study. Each
adverse event was described in detail, including,
onset time and date, offset time and date, descrip-
tion of occurrence, severity, relationship to inves-
tigational product, action taken, and outcome.
In each treatment period, blood samples (7mL)
for plasma assay of etamicastat and BIA 5-961
were taken at the following times: pre-dose, 0.5,
1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 48, and 72 hours
post-dose. Blood samples were drawn either by
direct venepuncture or via an intravenous cathe-
ter into lithium-heparin Vacutainer tubes (Becton
DickinsonUKLtd, Oxford, UK) and centrifuged
at approximately 1500 g for 10 minutes at 4C.
The resulting plasma was separated into two ali-
quots of 750mL and stored at -70C until required
for analysis.
Determination of plasma concentrations of
etamicastat and its acetylatedmetabolite BIA 5-961
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was performed at Algorithme Pharma Inc. (Laval,
QC, Canada) by liquid chromatography coupled
to a mass spectrometry system using a previously
validated method described elsewhere.[20] Cali-
bration curves, over the nominal concentration
ranges 10–1000 ng/mL, and a set of quality con-
trol samples (duplicates over five concentration
levels) were analyzed with each batch of study
samples. The quality control samples were used
to monitor the performance of the assay. The
data from the quality control samples showed
that the overall imprecision of the method, mea-
sured by the coefficient of variation, ranged from
8.2% to 11.2% for etamicastat and from 4.6% to
10.6% for BIA 5-961. The overall accuracy, mea-
sured as the proportion of the determined value
in relation to the true or nominal value, ranged
from 95.0% to 105.0% for etamicastat and from
96.4% to 103.4% for BIA 5-961. The lower limit of
quantification of the assay (LLOQ) was 10ng/mL.
Pharmacokinetic Analysis
The following pharmacokinetic parameters
for etamicastat and BIA 5-961 were derived by
non-compartmental analysis from the individual
plasma concentration versus time profiles: max-
imum observed plasma drug concentration (Cmax);
the time of occurrence of Cmax (tmax); area under
the plasma concentration-time curve (AUC)
from time zero to the last measurable concen-
tration (AUClast) [calculated by the linear trap-
ezoidal rule]; AUC from time zero to infinity
(AUC¥) [calculated from AUClast + (Clast/lz),
where Clast is the last quantifiable drug concen-
tration]; and t½ (calculated from ln 2/lz, where lz
is the apparent terminal rate constant calculated
by log-linear regression of the terminal segment
of the plasma concentration versus time curve).
Actual sampling times were used for the phar-
macokinetic analysis. Special consideration was
given to the estimation of lz and corresponding
t½ values. Values of lz were calculated from a
minimum of three datapoints. Those lz values
determined from three datapoints, and those
values calculated over a period that was less than
2-fold greater than the corresponding t½ values
were noted in the appropriate tables. Where an
AUC was extrapolated to infinity, the percentage
of the extrapolated area to the total area was as-
sessed, and if greater than 20%, the AUC value
was flagged as unreliable. Plasma concentrations
below the LLOQ (10 ng/mL) of the assay were
taken as zero for all calculations. Summary sta-
tistics of all data for each treatment and schedule
sampling time were reported, as appropriate, using
the geometric mean, arithmetic mean, standard
deviation (SD), coefficient of variation (CV), me-
dian, and range (minimum and maximum).
For the evaluation of the effect of food on eta-
micastat pharmacokinetics, the parameters AUC¥,
AUClast, and Cmax were the primary variables.
The effect of food on the pharmacokinetics of
etamicastat was studied in accordance with the
statistical method for testing relative bioavaila-
bility (e.g. bioequivalence) in which 90% con-
fidence intervals for the geometric mean ratio
(GMR) [point estimate] of the observed phar-
macokinetic parameters with food (fed = test) and
without food (fasting= reference) should be report-
ed. For such purpose, the etamicastat pharmaco-
kinetic parameters of interest (AUC¥, AUClast,
and Cmax) were compared using ANOVA. The
test procedure was analogous to equivalence
testing. ANOVA was used to test for differences
between test (fed condition) and reference (fast-
ing condition) for AUC¥, AUClast, and Cmax of
etamicastat. The pharmacokinetic parameters
were logarithmically transformed prior to analysis.
The 90% confidence intervals (CIs) for the GMR
of etamicastat and BIA 5-961 AUC¥, AUClast,
and Cmax were constructed, comparing test versus
reference treatments. In accordance with the guide-
lines for bioequivalence testing, the bioequivalence
was assumed when the 90% CI for the test/
reference GMR fell within the usually accepted
reference interval (80, 125).[27-29] The Wilcoxon
signed rank test was used to test for the difference
in tmax (secondary variable) between test and
reference treatments. An a-level of 0.05 was used
for defining statistical significance.
No results of previous studies in humans were
known at the time of defining the study design. A
sample size of 12 evaluable subjects was defined
for this study because it is the minimum sample
size required by the current regulatory guidance.[29]
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The post hoc power for the current study was
calculated as 96.29% for etamicastat Cmax, 99.99%
for etamicastat AUClast, and 99.99% for etami-
castat AUC¥.
The pharmacokinetic parameters were deter-
mined using WinNonlin Version 5.2 (Pharsight
Inc, Mountain View, CA, USA). The statistical
package SAS Version 9.1 (SAS Institute Inc,
Cary, NC, USA) was used in computations.
Tolerability Analysis
Adverse events were coded according to the
Medical Dictionary for Regulatory Activities
(MedDRA, version 12.0). Individual and summary
blood pressure, heart rate, and clinical laboratory
data were presented in tabular form with mean,
SD, median, and range, as appropriate. For the
laboratory safety data, out of range values were
flagged in the data listings and a list of clinically
significantly abnormal values was presented.
Results
Population
A total of 12 male subjects were enrolled in
and completed the study. The mean – SD demo-
graphic data were as follows: age 26.9 – 5.5 (range
19–34) years; height 176 – 7 (range 164–186) cm;
weight 73.8 – 10.5 (range 55–93) kg; and BMI
23.7 – 2.1 (range 20.0–27.0) kg/m2. All subjects
were Caucasian.
Pharmacokinetic Results
Mean plasma etamicastat and BIA 5-961 con-
centration versus time profiles and corresponding
pharmacokinetic parameters following a single
oral 200mg dose of etamicastat in fasting and fed
conditions are presented in figure 1 and table I.
All pharmacokinetic parameters could be reliably
estimated.
Etamicastat Cmax was reached between 1 and
2 hours post-dose in the fasting group, after
which concentrations declined with an approx-
imate mean apparent terminal t½ of 19.9 hours.
Following the standard meal, etamicastat Cmax
was reached between 2 and 5 hours post-dose,
and t½ was 19.6 hours. GMR and 90% CI for the
etamicastat pharmacokinetic parameters of in-
terest (AUC¥, AUClast, and Cmax) are given in
table II. The extent of exposure of etamicastat, as
reflected by AUClast and AUC¥, fulfilled the
claim of bioequivalence because the 90% CI fell
within the reference range (80, 125); however, the
exposure to etamicastat, as reflected by Cmax, did
not fit the claim of bioequivalence between test
(fed) and reference (fasting), because the 90% CI
fell outside the reference range. Etamicastat Cmax
decreased 28% as a result of food intake. Etami-
castat tmax was significantly delayed following
administration of etamicastat in the fed condition
compared with administration in the fasting
group (p < 0.001).
BIA 5-961 GMR and 90% CI showed a signif-
icant decrease of BIA 5-961 AUC¥, AUClast, and
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Fig. 1. Mean plasma concentration vs time profiles of (a) etamica-
stat and (b) BIA 5-961 following a single oral dose of etamicastat
200mg in fasting (reference) and fed (test) conditions (n =12).
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Cmax when etamicastat was administered in the
presence of food (table II). No statistical difference
on BIA 5-961 tmax (p < 0.05) following adminis-
tration of etamicastat in the fasting or fed con-
dition was found.
Figure 2 displays the individual etamicastat
and BIA 5-961 Cmax and AUC¥ pharmacokinetic
parameters. From figure 2, it is apparent that the
subgroup of five subjects (#03, #04, #06, #07, and
#08) who showed the lowest etamicastat AUC¥
values following administration of etamicastat
also showed the highest BIA 5-961 Cmax values.
These subjects probably presented a NAT2 rapid
acetylating phenotype, leading to faster biotrans-
formation of etamicastat into its acetylated me-
tabolite BIA 5-961.
Tolerability Results
During the course of the study, 4 (33.3%) of
12 subjects who constituted the safety population
reported a total of six treatment-emergent ad-
verse events (TEAEs). Two TEAEs (headache
and vagal reaction) were reported during the
fasting period, and four TEAEs during the fed
period (abdominal pain, asthenia, headache, and
intercostal pain). All TEAEs were mild to mod-
erate in intensity. There were no serious adverse
events or discontinuations due to adverse events.
No clinically relevant abnormalities were ob-
served in vital signs, ECG, or laboratory safety
tests during the study.
Discussion
The primary objective of the studywas to investi-
gate the effect of food on the pharmacokinetics of
etamicastat. Cmax, AUClast, and AUC¥ of eta-
micastat were defined as the main parameters for
the assessment of bioavailability and bioequiva-
lence of etamicastat administered in fasting and
fed conditions, which is in agreement with current
Table I. Pharmacokinetic parameters of etamicastat and BIA 5-961 following a single oral dose of etamicastat 200mg in fasting (reference)
and fed (test) conditions (n =12)
Analyte/ Statistics Cmax tmax AUClast AUC¥ lz t½
condition (ng/mL) (h) (ngh/mL) (ngh/mL) (L/h) (h)
Etamicastat
Fasting AMean –SD 229– 48 1.5 –0.5 1856– 818 2238 – 943 0.0416 –0.0197 19.9 –8.2
GMean (median) 224 (227) 1.4 (1.5) 1659 (2287) 2022 (2828) 0.0379 (0.0364) 18.3 (19.1)
Fed AMean –SD 166– 37 3.5 –1.2 1737– 794 2119 – 849 0.0391 –0.0132 19.6 –6.3
GMean (median) 162 (169) 3.3 (3.0) 1553 (1957) 1951 (2314) 0.0372 (0.0390) 18.7 (17.8)
BIA 5-961
Fasting AMean –SD 384– 311 2.7 –0.5 2396– 1802 2559 – 1836 0.1100 –0.0474 8.0 –4.6
GMean (median) 275 (186) 2.6 (3.0) 1827 (1189) 2009 (1326) 0.0987 (0.1200) 7.0 (5.8)
Fed AMean –SD 228– 173 4.1 –1.2 1840– 1332 2051 – 1375 0.0854 –0.0323 9.1 –3.0
GMean (median) 172 (110) 3.9 (5.0) 1450 (991) 1677 (1225) 0.0804 (0.0801) 8.6 (8.7)
kz= apparent terminal rate constant; AMean =arithmetic mean; AUC¥ = area under the concentration-time curve from time zero to infinity;
AUClast = area under the plasma concentration-time curve from time zero to the last measurable concentration; Cmax =maximum plasma
concentration; GMean = geometric mean; t½= elimination half life; tmax = time to Cmax.
Table II. Test/reference geometric means ratio (GMR) and 90% CI
of etamicastat and BIA 5-961 maximum plasma concentration
(Cmax), area under the concentration-time curve (AUC) from time
zero to the last measurable concentration (AUClast), and AUC from
time zero to infinity (AUC¥) following a single oral dose of etamicastat
200mg in fasting (reference) and fed (test) conditions (n =12)
Parameter Etamicastat BIA 5-961
Cmax
GMR (%) 72.27 62.42
90% CI 64.98, 80.38 56.77, 68.63
AUClast
GMR (%) 93.59 79.41
90% CI 89.28, 98.11 56.77, 68.63
AUC¥
GMR (%) 96.47 83.47
90%CI 91.67, 101.53 76.62, 90.93
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regulatory guidelines.[26,30] The 90% CI for the
fed/fasting etamicastat Cmax GMRare not contain-
ed within the acceptance interval (80, 125)[27,28]
and, therefore, it can be concluded that the rate of
systemic exposure to etamicastat does not fit the
claim of bioequivalence between administration
in fasting and fed conditions. Etamicastat Cmax
significantly decreased by 28% and tmax signif-
icantly increased, but AUClast and AUC¥ re-
mained within the acceptance interval, showing
that the extent of systemic exposure to etamica-
stat was not affected by the delay in absorption of
etamicastat in the presence of food. Although a
significant decrease in Cmax is not expected to have
an impact on the tolerability of a drug, it could
have a hypothetical impact on efficacy. However,
the inhibition of DbH by DbH blockers provides
gradual sympathetic modulation as opposed to
abrupt inhibition;[8] therefore, a delay in absorp-
tion and corresponding decrease in peak ex-
posure without a relevant change in the extent of
exposure (AUC) is not expected to be clinically
significant.
Etamicastat appeared to be metabolized to its
acetylated metabolite BIA 5-961, which is in
agreement with other studies.[19,20] Systemic ex-
posure to the metabolite BIA 5-961 decreased as
a result of food. However, this effect is not expect-
ed to have an impact on etamicastat tolerability
or efficacy since the metabolite is inactive.
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Fig. 2. Individual mean etamicastat (a) maximum plasma concentration (Cmax) and (b) area under the concentration-time curve from time
zero to infinity (AUC¥); and BIA 5-961 (c) Cmax and (d) AUC¥ values following a single oral dose of etamicastat 200mg in fasting (reference)
and fed (test) conditions (n =12).
134 Vaz-da-Silva et al.
ª 2011 Vaz-da-Silva et al., publisher and licensee Adis Data Information BV. Drugs R D 2011; 11 (2)
The pharmacokinetic results of the current
study are consistent with those of the 200mg dose
group of an entry-into-man study[19] in healthy
subjects administered with single oral doses of
etamicastat ranging from 2 to 1200mg in fasting
conditions. In the earlier study,[19] arithmetic
mean etamicastat Cmax was 202 ng/mL, AUClast
was 2026ngh/mL, AUC¥was 2230ngh/mL, and
t½ was 19.8 hours following a 200mg single dose
in a fasting condition; these results are close to
those reported in the fasting period of the current
study (229ng/mL, 1856ngh/mL, 2238ngh/mL,
and 19.9 hours, respectively).
The results of the current study show a large
interindividual variability in the pharmacokinetic
parameters of interest in both analytes (etamica-
stat and its metabolite) and in both study periods.
This interindividual variability is consistent with
that reported in previous studies[19,20] and is likely
to be as a result of differences in NAT2 genotype,
leading to different acetylating profiles. The clini-
cal consequence is that NAT2 genotyping may
be required for an adequate dosage definition of
etamicastat in patients. Etamicastat was well
tolerated in both study periods.
Conclusion
This exploratory study involving administra-
tion of etamicastat to healthy volunteers under
fasting conditions and with a high-fat meal in-
dicated that etamicastat Cmax was decreased 28%,
while AUC remained unchanged. This decrease
in peak exposure is not clinically significant, and
therefore etamicastat can be taken with or with-
out meals.
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